Foghorn Therapeutics Inc (NASDAQ:FHTX) — Market Cap & Net Worth
Market Cap & Net Worth: Foghorn Therapeutics Inc (FHTX)
Foghorn Therapeutics Inc (NASDAQ:FHTX) has a market capitalization of $249.42 Million ($249.42 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15764 globally and #3726 in its home market, demonstrating a -10.06% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Foghorn Therapeutics Inc's stock price $4.20 by its total outstanding shares 59385315 (59.39 Million). Also see Foghorn Therapeutics Inc assets under control for a full breakdown of the balance sheet.
Foghorn Therapeutics Inc Market Cap History: 2020 to 2026
Foghorn Therapeutics Inc's market capitalization history from 2020 to 2026. Data shows change from $1.20 Billion to $249.42 Million (-21.93% CAGR). Also see Foghorn Therapeutics Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Foghorn Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.01% | #428 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1541 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.01% | #219 of 263 |
Weight: Foghorn Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Foghorn Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Foghorn Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check FHTX live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
10.37x
Foghorn Therapeutics Inc's market cap is 10.37 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.20 Billion | $430.00K | -$68.80 Million | 2799.40x | N/A |
| 2021 | $1.36 Billion | $1.32 Million | -$101.32 Million | 1029.68x | N/A |
| 2022 | $378.88 Million | $19.23 Million | -$108.87 Million | 19.70x | N/A |
| 2023 | $383.04 Million | $34.16 Million | -$98.43 Million | 11.21x | N/A |
| 2024 | $280.30 Million | $22.60 Million | -$86.62 Million | 12.40x | N/A |
| 2025 | $320.68 Million | $30.91 Million | -$74.28 Million | 10.37x | N/A |
Competitor Companies of FHTX by Market Capitalization
Companies near Foghorn Therapeutics Inc in the global market cap rankings as of September 18, 2026. Review Foghorn Therapeutics Inc tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Foghorn Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Foghorn Therapeutics Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Foghorn Therapeutics Inc's market cap moved from $1.20 Billion to $ 249.42 Million, with a yearly change of -21.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $249.42 Million | -22.22% |
| 2025 | $320.68 Million | +14.41% |
| 2024 | $280.30 Million | -26.82% |
| 2023 | $383.04 Million | +1.10% |
| 2022 | $378.88 Million | -72.10% |
| 2021 | $1.36 Billion | +12.83% |
| 2020 | $1.20 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Foghorn Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $249.42 Million USD |
| MoneyControl | $249.42 Million USD |
| MarketWatch | $249.42 Million USD |
| marketcap.company | $249.42 Million USD |
| Reuters | $249.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Foghorn Therapeutics Inc
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mu… Read more